GlassScriptPhysician profile
Anam Baig
NPI 1972965150
$2,154.38
in general payments reported to CMS, 2019-2025
28 companies · $858 in 2025
The $858 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2022: $178 · 2023: $104 · 2024: $850 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $857.46 | 2024-2025 | |
| Lundbeck LLC | $193.53 | 2019-2022 | |
| Lilly USA, LLC | $133.24 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Ucb, INC. | $86.68 | 2025 | Fintepla |
| Neurelis, INC. | $82.32 | 2024-2025 | Valtoco |
| Boston Scientific Corporation | $79.33 | 2022-2025 | Watchman Flx |
| Pfizer INC. | $74.43 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $66.58 | 2024 | Ingrezza |
| Fisher & Paykel Healthcare INC | $59.28 | 2025 | Fisher & Paykel Healthcare |
| Impel Pharmaceuticals INC. | $50.59 | 2022-2023 | Trudhesa |
| Janssen Biotech, INC. | $43.79 | 2025 | |
| Emd Serono, INC. | $43.28 | 2024-2025 | |
| Microtransponder, INC. | $36.89 | 2024 | |
| Jazz Pharmaceuticals INC. | $34.82 | 2024 | |
| Philips North America LLC | $29.55 | 2024 | (Cm9) Amb Mon & Diag Und |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aucta Pharmaceuticals, INC. | $28.15 | 2024 | Motpoly Xr |
| Astrazeneca Pharmaceuticals LP | $27.08 | 2025 | Wainua |
| Takeda Pharmaceuticals U.S.A., INC. | $26.59 | 2024 | Hyqvia |
| Biogen, INC. | $25.92 | 2025 | Skyclarys |
| Acadia Pharmaceuticals INC | $24.75 | 2025 | Daybue |
| Medtronic USA, INC. | $23.16 | 2019 | |
| Revance Therapeutics, INC. | $20.98 | 2024 | Daxxify |
| Alexion Pharmaceuticals, INC. | $20.41 | 2025 | Ultomiris |
| Argenx US, INC. | $19.78 | 2023 | Vyvgart |
| Teva Pharmaceuticals USA, INC. | $17.02 | 2025 | Austedo Xr |
| Avanir Pharmaceuticals, INC. | $16.94 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.17 | 2019 | |
| Eisai INC. | $15.66 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anam Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.